DermTech (DMTK) Tops Q4 EPS by 7c

DermTech (NASDAQ: DMTK) reported Q4 EPS of ($0.48), $0.07 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $1.78 million.

“I am pleased with the growth of our Q4 sample volume, which reflects the demand for our PLA product, despite the challenging COVID environment. Over time we expect to monetize this sample volume by securing commercial payor coverage and growing our proportion of Medicare samples. This thesis is beginning to play out with some successful contracting efforts during the quarter,” said John Dobak, M.D., chief executive officer of DermTech. “While limited access to physician offices continues to impede our sales effort, I am proud of the way our commercial team has managed these headwinds. We are confident we can access very large market opportunities through our mission to transform the practice of dermatology, improve patient care, and help reduce melanoma deaths.”

For earnings history and earnings-related data on DermTech (DMTK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• SanDisk upgraded at JPMorgan after investor day; shares climb